Regulatory Q&A Forum
Ask questions, share knowledge, and get help from the regulatory community
With the introduction of new EU regulations like the Packaging and Packaging Waste Regulation (PPWR), how should economic operators, including medical device manufacturers, evolve their criteria for s...
While non-EU manufacturers often budget for an EU Authorized Representative (AR) under medical device regulations, the introduction of the Carbon Border Adjustment Mechanism (CBAM) adds a new layer of...
When preparing a premarket submission for a connected medical device, such as a Class II Software as a Medical Device (SaMD) or a networked patient monitor, how can sponsors effectively demonstrate co...
With the implementation of the Modernization of Cosmetics Regulation Act of 2022 (MoCRA), foreign cosmetic facilities marketing products in the United States must now designate a U.S. Agent. This requ...
When a small or medium-sized enterprise (SME) seeks to contract a "Person Responsible for Regulatory Compliance (PRRC) as a Service" to meet EU MDR Article 15 requirements, how can the organization mo...
As medical device manufacturers plan their budgets for 2025, securing a Person Responsible for Regulatory Compliance (PRRC) remains a critical requirement under the EU MDR, particularly for companies ...
As the EU AI Act creates new compliance obligations alongside the GDPR and MDR/IVDR, how should manufacturers of AI-enabled medical devices and Software as a Medical Device (SaMD) approach the selecti...
For AI companies based outside the EU that process the personal data of individuals within the Union, appointing a representative under GDPR Article 27 is a fundamental compliance requirement. As the ...
With the EU AI Act establishing new requirements for non-EU providers of high-risk AI systems, selecting an EU Authorized Representative (AR) becomes a critical compliance step. Beyond simply having a...
With the EU AI Act introducing new compliance obligations, many non-EU providers of AI systems will soon be required to appoint an EU-based Authorized Representative (AR). While this concept is famili...
With the implementation of the Modernization of Cosmetics Regulation Act (MoCRA), foreign cosmetic product facilities that manufacture or process products for the U.S. market face a new requirement: d...
Under the Modernization of Cosmetics Regulation Act (MoCRA), foreign cosmetic product facilities that manufacture or process products for the U.S. market must designate a United States Agent. Given th...
When budgeting for EU MDR compliance for 2026 and beyond, how can a medical device manufacturer accurately forecast the cost of engaging a "Person Responsible for Regulatory Compliance (PRRC) as a Ser...
As medical device manufacturers plan their budgets for 2026, securing a "Person Responsible for Regulatory Compliance" (PRRC) as a service is a critical consideration under the EU MDR. While a precise...
For a non-EU manufacturer whose products contain Per- and Polyfluoroalkyl Substances (PFAS), what are the critical factors to evaluate when selecting a REACH Only Representative (OR) to manage complia...
As non-EU chemical manufacturers plan their compliance budgets for 2026, what are the key components and variables that determine the total cost of a REACH Only Representative (OR) service, and how ca...
With the EU AI Act establishing new compliance requirements, non-EU providers of regulated AI systems must appoint an EU-based Authorized Representative (AR). While specific pricing is determined by i...
With the upcoming EU AI Act mandating that many non-EU providers appoint an EU-based Authorized Representative (AR), how does this new requirement impact AI system providers, particularly those also r...
For foreign cosmetic establishments, the Modernization of Cosmetics Regulation Act (MoCRA) mandates the designation of a U.S. Agent as a prerequisite for facility registration with the FDA. While comp...
With the Modernization of Cosmetics Regulation Act (MoCRA) now requiring foreign cosmetic facilities to designate a U.S. Agent, many firms are evaluating the associated costs. However, a simple price ...